TELADOC HEALTH, INC.Teladoc Health, Inc. • April 26th, 2024 • Services-offices & clinics of doctors of medicine
We are pleased that you have agreed to serve as the Interim Chief Executive Officer (“Interim CEO”) of Teladoc Health, Inc. (the “Company”) effective April 5, 2024. The purpose of this letter agreement (the “Letter Agreement”) is to document your duties and the compensation that you will receive for your service as Interim CEO. Reference is made to your Executive Severance Agreement with the Company, dated as of June 24, 2019 (the “Severance Agreement”). Terms used but not otherwise defined herein shall have the meaning set forth in the Severance Agreement.
TELADOC HEALTH, INC.Separation Agreement • April 26th, 2024 • Teladoc Health, Inc. • Services-offices & clinics of doctors of medicine
Your last day of employment with Teladoc Health, Inc. (the “Company”) was April 5, 2024 (“Separation Date”). In order to receive the separation benefits provided in Section 5(b)(i) of the Amended and Restated Executive Employment Agreement between you and the Company, dated as of June 16, 2015 (as amended October 29, 2019, the “Employment Agreement”) which are set forth in Exhibit A to this Release Agreement (“Separation Benefits”), less all required withholdings and deductions, as provided under the Employment Agreement, you must sign this Release Agreement (this “Release”).
AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • April 26th, 2024 • Teladoc Health, Inc. • Services-offices & clinics of doctors of medicine
This Amendment No. 2 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Adam Vandervoort, an individual resident in the State of Connecticut (“Executive”), is made as of April 26, 2024.
RETENTION BONUS AGREEMENTRetention Bonus Agreement • April 26th, 2024 • Teladoc Health, Inc. • Services-offices & clinics of doctors of medicine • New York
This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Adam Vandervoort (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.”
